Risk factors

NewAmsterdam Pharma (NAMS) risk factors

Item 1A of every NewAmsterdam Pharma Co. N.V. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open NAMS in Gloom →
NewAmsterdam Pharma's chart, financials and news, free in your browser.Open NAMS in Gloom →
  • FY2025 10-K risk factors
    107 risks13 new4 dropped18 reworded

    Obicetrapib’s risks now emphasize European commercialization through Menarini and building a U.S. sales organization.

    Filed Feb 18, 2026
  • FY2024 10-K risk factors
    98 risks

    NewAmsterdam Pharma is entirely dependent on obicetrapib for treating cardiometabolic diseases, facing substantial clinical, regulatory, and commercialization hurdles.

    Filed Feb 26, 2025